Objective To explore the efficacy of Longdanxiegan pellets in the treatment of Graves'orbitopathy. Methods 87 patients were randomly assigned to receive conventional therapy with Western medicines ( control goup, n = 41 ), or conventional therapy plus Longdanxiegan pellets ( study group, n= 46 ). The degree of exophthalmos and the changes in thyroid function were compared between the two groups during a one-year follow-up. Results 62 ( 71.3% ) were followed up for one year. There was no statistical difference between the two groups in degree of exophthalmos ( mild, ranging between 20mm ), sex ratio,age, and course of disease. After treatment, The degree of exophthalmos and levels of FT3 and FT4 were significantly lower in the study group than in the control group whereas TSH level was significantly higher( P< 0.05 ). No obvious adverse reactions including liver and renal dysfunction were found. Conclusions Longdanxiegan pellets are not only effective to Graves' orbitopathy but also to hyperthyroidism. They are safe and worth being clinically used.%目的 评价龙胆泻肝丸治疗Graves眶病的疗效.方法 将87例Graves眶病患者随机分为观察组(46例)及对照组(41例),后者按照常规西药治疗,观察组在对照组基础上加用龙胆泻肝丸(6 g,bid);随访1年,比较治疗前后突眼度及甲状腺功能的变化.结果 共有62例患者坚持1年随访(71.3%);治疗前两组患者的突眼度无统计学差异,均属于轻度(波动于20mm之间),且年龄、性别构成及病程均差异无显著性.治疗后观察组患者的突眼度明显低于对照组;观察组甲状腺功能示FT3及FT4低于对照组,而TSH明显高于对照组(P<0.05).两组患者无明显肝肾功能损害等不良反应.结论 龙胆泻肝丸对甲状腺功能亢进症本身及其眼征具有双重治疗作用,且其安全性较理想,可在临床参考使用.
展开▼
